Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: March 26, 2023
Home
2023
March
26
26
Mar
2023
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
0
0
March 26, 2023
March 26, 2023
26
Mar
2023
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
0
0
March 26, 2023
March 26, 2023
